Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.

Arina Miyoshi Hiraku KamedaSo NagaiAkinobu NakamuraAika MiyaTakahiro TakaseTatsuya AtsumiHideaki Miyoshi

Published in: Journal of diabetes investigation (2020)

Switching to Dmab from BP or SERM is beneficial to prevent osteoporosis progression in postmenopausal patients with type 2 diabetes mellitus patients.

Keyphrases

postmenopausal women
bone mineral density
end stage renal disease
estrogen receptor
newly diagnosed
chronic kidney disease
ejection fraction
peritoneal dialysis
prognostic factors
small molecule
patient reported outcomes
giant cell